Some have described BioPorto as a “one trick pony” – we tend to disagree….
EPO (the European Patent Organisation) have on october 25th 20111 sent a reply to BioPorto regarding the application for a patent covering measurement of ACP-PCI (and the APACHE II score).
BioPorto have defined a range within which patients suffering from severe sepsis can benefit from APC-treatment
EPO concludes that is is quite easy for BioPorto to obtain the patent – if they include some minor alterations that EPO wishes to see. EPO gives BioPorto 4 months to concede
Xirgis – until recently the only medication for Sepsis have since then been taken of the market, so there is presently a vacuum. However as severe sepsis is deadly and as the number of deaths from Sepsis is rising – Eli Lily will probably make an effort to have its product relaunched
Xirgis was taken of the market because there were limited positive results – this is (in our opinion) a major mistake – administered correctly patients would benefit from treatment with Xirgis – but you must have a clear identification of those that you give the treatment, otherwise Xirgis may actually worsen the patients health..
[EDIT:]
The APC-PCI patent has been issued by USPTO. (USA)
